Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 9Central Nervous System Neoplasms 6Brain Neoplasms 6Oligodendroglioma 3Gliosarcoma 3Astrocytoma 3Sarcoma 2Optic Nerve Glioma 2Neoplasm Metastasis 2Glioma 2Ependymoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Vipoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Prolactinoma 1Pituitary Neoplasms 1Pheochromocytoma 1Ovarian Neoplasms 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neuroectodermal Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia Type 2b 1

Interventions

Temozolomide 1Microarray Analysis 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Prolactinoma × Temozolomide × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡